Denali Therapeutics Cash Flow Statement
NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
19.45+0.78 (+4.18%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Denali Therapeutics free cash flow
In fiscal 2025, Denali Therapeutics generated -$412.6 million of operating cash flow and spent $9.5 million on capital expenditures. That left free cash flow of -$422.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Denali Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -512.54M | -422.77M | -145.22M | -325.99M | -290.58M | 71.14M | -197.61M | -36.24M | -88.19M | -86.65M |
| Net Income growth (YoY) | — | — | — | — | -508.49% | — | — | — | — | — |
| Depreciation & Amortization | 11.18M | 7.79M | 16.73M | 10.38M | 8.59M | 8.53M | 7.99M | 7.42M | 3.08M | 1.47M |
| Stock-Based Compensation | 99.63M | 102.88M | 108.10M | 99.85M | 85.25M | 50.35M | 38.38M | 18.79M | 4.41M | 2.95M |
| Change in Working Capital | -8.06M | -1.04M | -1.66M | -31.80M | -21.09M | -31.45M | 1.42M | 49.96M | 280.00K | -372.00K |
| Operating Cash Flow | -412.60M | -347.69M | -357.99M | -244.72M | -211.39M | 416.15M | -151.58M | 50.12M | -76.64M | -71.91M |
| Capital Expenditures | -9.50M | -15.91M | -12.94M | -17.83M | -8.50M | -3.10M | -17.92M | -3.39M | -2.88M | -6.13M |
| Investing Cash Flow | 255.28M | -88.76M | 249.31M | -141.39M | -21.63M | -623.21M | 147.71M | -287.42M | -41.17M | -219.00M |
| Financing Cash Flow | 189.22M | 484.30M | 17.82M | 310.67M | 19.35M | 634.75M | 6.19M | 97.02M | 296.32M | 300.48M |
| Net Change in Cash | 31.90M | 47.85M | -90.86M | -75.43M | -213.67M | 427.69M | 2.33M | -140.29M | 178.52M | 9.56M |
| Free Cash Flow | -422.10M | -363.61M | -370.93M | -262.55M | -219.89M | 413.06M | -169.50M | 46.72M | -79.51M | -78.04M |
This table shows 10 annual periods of Denali Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow DNLI's reporting calendar. What is a cash flow statement?